European Medicines Agency Rejected Single-Trial Standards
The EMA has published an editorial opposing the shift toward relying on a single pivotal clinical trial for drug approvals.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Should government agencies prioritize faster drug approvals over requiring multiple clinical trials for new medicines?
The European Medicines Agency has formally rejected the push to adopt a single-trial drug approval standard. The agency maintains that multiple clinical trials are necessary to ensure robustness across diverse settings.
Why it matters
The agency argues that rigid requirements regarding trial numbers should not undermine the goals of clinical development, highlighting a split in global regulatory philosophy. This position directly challenges recent moves by the FDA to prioritize one pivotal study.
The EMA emphasizes that multiple trials provide necessary evidence robustness, differing from the FDA policy adopted in June 2026 which allows for single pivotal studies. Regulators now propose that developers identify knowledge gaps to prove benefits outweigh risks.
The players
European Medicines Agency
The agency is responsible for the scientific evaluation, supervision, and safety monitoring of medicines in the European Union.
FDA
The U.S. Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.
Vinay Prasad
He is a former official at the FDA who advocated for the end of the agency's long-standing two-trial requirements.
Marty Makary
He is a former FDA official who worked alongside Vinay Prasad to push for changes in the agency's clinical trial approval standards.
The details
The European Medicines Agency published an editorial outlining its preference for evidence-based drug research rather than fixed trial quantity requirements. Developers are being encouraged to structure evidence generation to answer research questions rather than strictly adhering to specific trial numbers.
Timeline
In February 2026, FDA executives announced the end of the traditional two-trial dogma.
The FDA adopted the one pivotal study policy in June 2026.
EMA leadership outlined the agency view in an editorial published in September 2026.
The Tech Race
This regulatory divergence marks a departure from the FDA's one pivotal study policy by emphasizing the necessity of multiple trial datasets. It positions the EMA as a distinct counterweight to the American push for accelerated drug development through reduced trial volume.
The regulatory split may complicate development timelines for pharmaceutical companies seeking simultaneous international approval for new therapies. Developers will likely need to align their evidence-gathering strategies to satisfy these conflicting global standards.
The takeaway
The EMA's stance underscores a fundamental debate over whether speed or evidentiary volume better serves patient safety in drug development. Companies will face increased pressure to balance these diverging international requirements to secure global market access.
Further reading
For more on the current regulatory climate, see Biotech.
Source note: This article includes information reported by BioXconomy.
Live Poll
Should government agencies prioritize faster drug approvals over requiring multiple clinical trials for new medicines?
